Free tool
FAERS Monitor: Lumify Preservative Free
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218424 or its brand name (Lumify Preservative Free, Brimonidine Tartrate). Reports on generic versions are filed under their own applications.
Reports
3,486
Serious
1,720
49% of reports
Hospitalization
723
Death reported
189
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain303
- eye irritation230
- drug ineffective205
- product use issue198
- fatigue185
- ocular hyperaemia174
- headache172
- vision blurred170
- dizziness146
- product dose omission issue127
- death119
- off label use116
- diarrhoea113
- somnolence107
- dyspnoea102
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 39 |
| 2006 | 36 |
| 2007 | 53 |
| 2008 | 37 |
| 2009 | 45 |
| 2010 | 55 |
| 2011 | 81 |
| 2012 | 77 |
| 2013 | 44 |
| 2014 | 52 |
| 2015 | 93 |
| 2016 | 109 |
| 2017 | 112 |
| 2018 | 146 |
| 2019 | 159 |
| 2020 | 275 |
| 2021 | 213 |
| 2022 | 245 |
| 2023 | 291 |
| 2024 | 323 |
| 2025 | 425 |
| 2026 | 548 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,673 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 303 | 32.6 | 29.2 | 9,216 |
| eye irritationSignal | 230 | 24.2 | 21.4 | 5,086 |
| ocular hyperaemiaSignal | 174 | 22.2 | 19.2 | 3,496 |
| vision blurredSignal | 170 | 7.5 | 6.5 | 953 |
| product use issueSignal | 198 | 6.4 | 5.6 | 897 |
| somnolenceSignal | 107 | 3.2 | 2.7 | 162 |
| product dose omission issueSignal | 127 | 2.6 | 2.2 | 126 |
| dizziness | 146 | 1.8 | 1.5 | 49 |
| headache | 172 | 1.7 | 1.4 | 45 |
| fatigue | 185 | 1.4 | 1.2 | 25 |
| dyspnoea | 102 | 1.1 | 0.9 | 1 |
| diarrhoea | 113 | 1.1 | 0.9 | 0 |
| drug ineffective | 205 | 0.9 | 0.8 | 1 |
| death | 119 | 0.8 | 0.7 | 4 |
| off label use | 116 | 0.8 | 0.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.